ImmunoGen announces positive decisions for Roche's Kadcyla

theflyonthewall.com

ImmunoGen announced positive decisions for Roche's Kadcyla in both the European Union and Japan after Kadcyla was approved for marketing in the US earlier this year. Roche is conducting a number of studies assessing Kadcyla for potential additional uses. These include for the first-line treatment of HER2-positive metastatic breast cancer, for early stage HER2-positive breast cancer and for advanced HER2-positive gastric cancer.

View Comments (0)